


Microba launches GI Navigator in Australia and the UK

Microba Life Sciences Limited (ASX: MAP) (Microba or the Company) is pleased to announce the commercial launch of GI Navigator, a new clinical gut test designed to help healthcare practitioners resolve complex gastrointestinal (GI) symptoms, with easy to use clinical guidance built on the latest science and full microbiome mapping.¹ GI Navigator is available from today in Australia and the United Kingdom.

Key points

- GI Navigator is now fully available to healthcare practitioners in Australia and the UK. Over 150 tests have already been ordered by leading clinicians in the beta program ahead of launch.
- Over 400 practitioners joined the GI Navigator waitlist, including more than 150 who had not previously ordered a Microba test.
- A world-first full microbiome and gut test. Results from a single at-home stool sample and a short patient questionnaire are interpreted by Microba's proprietary Clinical Logic Engine to give practitioners clear interpretations and a personalised management plan².
- Designed to make microbiome testing practical for medical doctors, including GPs and gastroenterologists, a significant next segment of the healthcare practitioner market for Microba's tests.
- Addresses an estimated 82 million patients who present each year with lower GI symptoms across seven major markets, around half of whom do not get a resolution through routine care.^{3,4}
- Further information on GI Navigator, including a demonstration video, is available at www.microba.com/practitioners/products/gi-navigator



A/Prof Lutz Krause, Chief Scientific Officer at Microba, commented:

"The launch of GI Navigator is a major milestone for Microba. Persistent gut symptoms often have more than one cause, so a single test result rarely gives the full answer. GI Navigator brings together our world-leading microbiome technology and years of clinical data, combining the microbiome, gut physiology, pathogen screening and the patient's own symptoms in one report. Drawing on more than 2,500 peer-reviewed studies, it gives doctors clear interpretations and a practical plan for patients with persistent gut symptoms. It is the result of several years of work by our science team, shaped by feedback from the clinicians in our beta program. The response from practitioners ahead of launch has been very encouraging, with over 150 tests already ordered and more than 400 practitioners on the waitlist. GI Navigator has been launched in both Australia and the United Kingdom on our existing platform and practitioner base."

Addressable market of over 82 million patients

Persistent gut symptoms such as bloating, abdominal pain, diarrhoea and constipation are among the most common reasons people see a doctor, and around 40% of people live with an ongoing functional gut disorder.⁵ An analysis of billing and claims data estimated an addressable population of over 82 million patients with lower GI symptoms across the US, Germany, Italy, Spain, France, the United Kingdom and Australia.³ The current

standard of care leaves an estimated 50% of these patients without a resolution to their symptoms.⁴

Routine tests generally look for a single cause, such as an infection or inflammation. Outdated microbiome protocols and standard gut testing can leave practitioners and patients without answers, prolonging patient suffering. Microbiome testing gives a broader view of gut health, but interpreting the results has required time and specialist knowledge, limiting its uptake among time-poor medical doctors. GI Navigator has been developed to address this.

About GI Navigator

GI Navigator is designed for patients with complex or persistent GI symptoms. From one stool sample collected at home and a 15-minute online questionnaire completed by the patient, GI Navigator delivers:

- Superior coverage – full microbiome mapping⁶, patient presentation assessment, gut physiology and pathogen screening, all in one test.
- Clear, accessible interpretations – results that healthcare practitioners can readily understand and explain to their patients, based on the latest microbiome science.
- Personalised, prioritised actions – each interpretation is mapped to a consolidated set of personalised, prioritised suggested next steps across diet, supplements, exercise and more.²
- Practice support features - a range of tools to make practice workflows easier and more productive, including an intuitive, easy-to-use web portal, in-clinic collaboration features, flexible payment terms, live interactive report sharing, access to in-house clinical support and 24-hour customer support.

Results are typically available within two to four weeks from receipt at Microba's laboratory. At the follow-up consultation, practitioners can share an interactive version of the report with the patient and their family, or with other healthcare providers if specialist care is needed.

GI Navigator expands the Microba portfolio and gives practitioners a choice of test across a wider range of gut health concerns. GI Navigator focuses on complex or persistent GI symptoms, while Microbiome Explorer is used to evaluate a broader range of systemic health issues. Practitioners can now choose the test that best suits the patient in front of them.

INTRODUCING

GI Navigator

A new era of clinical gut testing is here

MICROBA

GI Navigator

COLLECTION KIT

REPORT PORTAL

MICROBA.COM

EXPECT BETTER

The advertisement features a white box containing the product name 'GI Navigator' in large, colorful letters. Below it is the tagline 'A new era of clinical gut testing is here'. To the right of the text is a white box labeled 'GI Navigator' with 'COLLECTION KIT' and 'REPORT PORTAL' written on it. Next to the box is a tablet displaying a colorful, interactive report with various charts and graphs. The background is a light gray gradient.

Commercial launch

- GI Navigator is available from today in Australia and the United Kingdom and is ordered through the Microba practitioner portal.
- The introductory price is \$549 in Australia and £399 in the United Kingdom, paid by either the patient or the practitioner.
- The test can be ordered immediately by Microba's existing network of clinicians (over 900 in Australia and over 300 in the United Kingdom at 30 June 2026).
- The launch is supported by email and social media campaigns reaching healthcare practitioners in Microba's network, together with digital and print advertising, and practitioner events in Australia and the United Kingdom during October and November.
- Testing is processed through Microba's existing laboratory and digital platform.
- Microba will report GI Navigator sales in its quarterly activities reports, starting with the December 2026 quarter.
- Further information on GI Navigator, including a demonstration video, is available at www.microba.com/practitioners/products/gi-navigator

1 GI Navigator is for use by healthcare practitioners as a clinical decision support tool. Personalised management plans are to be determined by the treating healthcare professional, and interpretations are intended to inform, not replace, clinical judgement.

2 Suggested actions are intended to inform clinical management, not replace the judgement of the treating healthcare professional.

3 Assessment completed with Boston based MedTech specialist consultancy Veranex Inc. Assessment analysed US Medicare claims for target patient populations, extrapolated Private and Medicaid numbers, populations and prevalence adjusted for key global markets outside of the US including Germany, Italy, Spain, France, United Kingdom and Australia.

4 Gordon, J., Miller, G., & Valenti, L. (2015). The management of unresolved gastrointestinal symptoms in Australian general practice. Australian Family Physician, 44(9), 621-623.

5 Sperber, A. D., Bangdiwala, S. I., Drossman, D. A., et al. (2021). Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome Foundation Global Study. Gastroenterology, 160(1), 99-114. Based on an internet survey of 54,127 adults across 26 countries.

6 100% coverage of all gut microbial species described in Almeida et al. 2021, Nature Biotechnology, along with additional species, including eukaryotes.

This announcement has been authorised for release by the Board of Directors.

For further information, please contact:

Investor / Media Relations

investor@microba.com

<https://ir.microba.com/welcome>

About Microba Life Sciences Limited

Microba is at the forefront of microbiome health and human care. With world-leading science, insights and collaboration tools, Microba's vision is to deliver clinical-grade microbiome tests that help people live healthier, happier lives. Better science. Better insights. Better health. Microba - Expect better. www.microba.com